Product liability litigation regularly involves the highest stakes in cases of extreme complexity. Faced with such franchise-threatening matters, the world’s leading corporations trust Paul, Weiss to lead them to victory. Our superior ability to establish a winning, long-term strategy, our unique skill at breaking down and presenting complicated material, and our vaunted trial prowess make us counsel of choice in many of the most important product liability lawsuits.
Paul, Weiss client Pfizer achieved a major victory in the second Zoloft birth defects case to go to trial in the U.S. At the conclusion of an eight-day trial, a Philadelphia jury returned a complete defense verdict and concluded that Pfizer's warnings about the risks of Zoloft were adequate.
As reported in Bloomberg, Reuters and other media outlets, Paul, Weiss client Pfizer achieved a major victory in the first Zoloft birth defects case to go to trial in the U.S. At the conclusion of a seven-day trial, a St. Louis jury returned a complete defense verdict in under two hours. The jury rejected the plaintiff's allegations that a mother's use of Zoloft in the first trimester of her pregnancy caused her child's cardiac birth defect.
As reported by Thomson Reuters and Law.com, Paul, Weiss client Pfizer Inc. achieved a major victory when a federal court granted the company's motion for summary judgment in In Re Pfizer Inc. Securities Litigation, a securities class action filed in the United States District Court for the Southern District of New York involving decade-old disclosures related to Celebrex and Bextra.